FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Paul G KluetzPatricia KeeganGeorge D DemetriKatherine ThorntonJoohee SulJanice KimHarvey KatzenLaurie Beth BurkeRobert Donald HarveyElleni AlebachewSundeep AgrawalAbhilasha NairMartha DonoghueWilliam F PierceStacy S ShordJennifer J GaoRichard PazdurPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The FDA conducts independent reviews of scientific data obtained with investigational drug products to ensure that they are safe and effective. As a result of this process, FDA-approved product labeling is generated that is considered one of the most trusted sources of information for use of an approved drug. But FDA approval is only the beginning of the life cycle of a new drug; the first oncology drugs now have more than 7 decades of clinical experience in the postmarketing setting. Due, in part, to lack of incentives, some companies may not seek inclusion of new data, other than new safety information, in FDA-approved product labeling. Ensuring that product labeling provides adequate directions for use is important for all drugs, including older therapies that may form the backbone of many standard combination regimens for pediatric and adult cancers. Project Renewal is an FDA Oncology Center of Excellence pilot program that leverages expertise from the clinical and scientific oncology communities to review published literature and generate a drug-specific product report summarizing data that may support updates to FDA-approved product labeling. This article provides a broad overview of Project Renewal's collaborative pilot process for identifying and assessing literature supporting potential labeling updates, while engaging the oncology community to increase awareness of FDA's evidentiary standards and deliberative processes used when considering the addition of new indications and dosing regimens to product labeling.
Keyphrases
- palliative care
- drug administration
- quality improvement
- systematic review
- electronic health record
- healthcare
- mental health
- big data
- drug induced
- adverse drug
- life cycle
- randomized controlled trial
- clinical trial
- study protocol
- emergency department
- community dwelling
- hepatitis c virus
- health information
- climate change
- artificial intelligence
- data analysis
- hiv testing